This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
The post Indian pharmaceutical patent prosecutio…
Indian pharmaceutical patent prosecution: The changing role of Section 3(d) Read Post »
This paper was originally published by Qiaolei Jiang and Chunjuan Luan in Globalization and Health 2018 14:92 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). Abstract Background Despite the …
Patents filed since 1995 last for 20 years from the date of patent application filing. This is true for “utility” patents, but the terms for certain other, less common types…
The post How Long Do Drug Patents Last? appeared first on DrugPatentWatch – M…
This article was originally published by Basavaraj S, Guru V. Betageri in Acta Pharmaceutica Sinica B Volume 4, Issue 1, February 2014, Pages 3-17 under a Creative Commons License. Abstract Drug discovery and development…
The post Can formulation and d…
This paper was originally published by T. Joseph Mattingly, Joseph F. Levy, Julia F. Slejko, Nneka C. Onwudiwe, and Eleanor M. Perfetto in PharmacoEconomics Volume 36, Issue 9 under a Creative Commons…
The post Estimating Drug Costs: How do Manufacture…
This paper was originally published by Toon van der Gronde, Carin A. Uyl-de Groot, and Toine Pieters in PLoS ONE 12(8): e0182613 under a creative commons license. Abstract Context Recent public outcry…
The post Addressing the challenge of high-priced p…
The theoretical construct of what happens when drug patents expire is simple and appealing (to consumers, anyway). A name brand drug patent expires, generics are waiting in the wings to…
The post What Happens When a Drug Patent Expires? appeared first …
This paper was originally published by Harinder Singh Chahal, Jeffrey S Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, and Peter G Lurie in Journal of the International AIDS…
The post The US Food and Drug Administration’s tentative…
This paper was originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017 under a …
The post Giving Drugs a Second Chance: Overc…
Litigation related to drug patents, whether it be direct patent challenges, contract disputes, or other cases, can provide direct intelligence (through disclosures of competitive intelligence) or indirect intelligence through exposure…
The post Improve…